CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab

Alzheimer s & Dementia, Год журнала: 2024, Номер 20(11), С. 7940 - 7953

Опубликована: Окт. 6, 2024

Abstract INTRODUCTION Growing evidence suggests a role for neuroinflammation in Alzheimer's disease (AD). We investigated complement pathway activity AD patient cerebrospinal fluid (CSF) and evaluated its modulation by the anti‐tau antibody semorinemab. METHODS Immunoassays were applied to measure CSF proteins C4, factor B (FB), C3 their cleavage fragments C4a, C3a, Bb (Bb) patients separate cognitively unimpaired (CU) cohort. RESULTS All measured increased versus CU subjects, with C4a displaying most robust increase. Finally, semorinemab did not have significant pharmacodynamic effect on proteins. DISCUSSION Elevated levels of C3, Bb, FB are consistent activation brains. Despite showing reduction soluble tau species, impact protein or activity. Further studies needed determine value as biomarkers AD. Highlights Cerebrospinal (AD) compared Baseline correlated neuro‐axonal degeneration glial patients. The investigational relative placebo arm.

Язык: Английский

Pharmacological and Therapeutic Innovation to Mitigate Radiation-Induced Cognitive Decline (RICD) in Brain Tumor Patients

Cancer Letters, Год журнала: 2025, Номер unknown, С. 217700 - 217700

Опубликована: Апрель 1, 2025

Язык: Английский

The Activation of Microglia by the Complement System in Neurodegenerative Diseases

Ageing Research Reviews, Год журнала: 2024, Номер unknown, С. 102636 - 102636

Опубликована: Дек. 1, 2024

Язык: Английский